Illinois News Desk

Delveinsight Business Research LLP

DelveInsight’s “Gorlin Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gorlin Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Gorlin Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Gorlin Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Gorlin Syndrome: An Overview

Gorlin Syndrome, also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-–Goltz syndrome is an infrequent multisystemic disease that is inherited in an autosomal dominant way and shows a high level of penetrance and variable expressiveness. Nevoid basal cell carcinoma syndrome (NBCCS) is known to be a rare autosomal dominantly inherited entity that is characterized most strikingly by the development of cutaneous basal cell carcinomas from an early age, typically puberty, although in some cases, it may occur earlier in childhood. Mutations in the PTCH1 gene cause Gorlin syndrome. This gene provides instructions for making a protein called patched-1, which functions as a receptor.

Gorlin Syndrome Market Key Facts

• According to the National Institute of Health (NIH), United States, Gorlin syndrome affects an estimated 1 in 31,000 people. While more than 1 million new cases of basal cell carcinoma are diagnosed each year in the United States, less than 1% of these skin cancers are related to Gorlin syndrome.

• Cancer Research Organization (United Kingdom) suggests that Gorlin syndrome affects about 1 in 31,000 people. Between 70 and 80 out of every 100 people (70-80%) with Gorlin syndrome have someone else in their family with it and have inherited a genetic mutation from one of their parents.

• A study conducted by M. Lorenzo et al. titled “Nevoid basal cell carcinoma syndrome (Gorlin syndrome)” states that the estimated prevalence varies from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1.

• According to Alison M et al., 2019, the prevalence of Gorlin syndrome is estimated at 1 per 40,000-60,000.

• The disease affects men and women in rather equal distribution (1:1.3). Although the disease affects all races, African-Americans and Asians represent only 5% of cases and more often are incidentally diagnosed with extracutaneous findings, such as odontogenic keratocyst, as compared to BCCs.

Gorlin Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Gorlin Syndrome pipeline therapies. It also thoroughly assesses the Gorlin Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Gorlin Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Gorlin Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Gorlin Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Gorlin Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Gorlin Syndrome Epidemiology, Segmented as –

• Prevalent cases of Gorlin Syndrome (2019-32)

• Diagnosed cases of Gorlin Syndrome (2019-32)

• Treatable cases of Gorlin Syndrome (2019-32)

Gorlin Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gorlin Syndrome market or expected to be launched during the study period. The analysis covers the Gorlin Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Gorlin Syndrome drugs based on their sale and market share.

The report also covers the Gorlin Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Gorlin Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Gorlin Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/gorlin-syndrome-market

Gorlin Syndrome Therapeutics Analysis

Several major pharma and biotech giants are actively developing novel therapies for the treatment of Gorlin syndrome. Currently, Palvella Therapeutics is leading the therapeutics market with its Gorlin-syndrome drug candidates in the most advanced stage of clinical development.

Gorlin Syndrome Companies Actively Working in the Therapeutics Market Include

• Palvella Therapeutics

• PellePharm

• Ascend Biopharmaceuticals

• HedgePath Pharmaceuticals

• Mayne Pharma

• Leo-Pharma

• Phyton Biotech

And many others

Emerging and Marketed Gorlin Syndrome Therapies Covered in the Report Include:

• PTX-022: Palvella Therapeutics

• SUBA-Itraconazole: HedgePath Pharmaceuticals/ Mayne

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/gorlin-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Gorlin Syndrome Competitive Intelligence Analysis

4. Gorlin Syndrome Market Overview at a Glance

5. Gorlin Syndrome Disease Background and Overview

6. Gorlin Syndrome Patient Journey

7. Gorlin Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Gorlin Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Gorlin Syndrome Unmet Needs

10. Key Endpoints of Gorlin Syndrome Treatment

11. Gorlin Syndrome Marketed Therapies

12. Gorlin Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Gorlin Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Gorlin Syndrome Market Outlook (In US, EU5, and Japan)

16. Gorlin Syndrome Companies Active in the Market

17. Gorlin Syndrome Access and Reimbursement Overview

18. KOL Views on the Gorlin Syndrome Market

19. Gorlin Syndrome Market Drivers

20. Gorlin Syndrome Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/gorlin-syndrome-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market

“Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research